BioStock: Status report Elicera Therapeutics – Pushing the boundaries of immuno-oncology
Immuno-oncology has been changing cancer therapy during the last decade. On the front line of this development is Swedish Elicera Therapeutics – a clinical stage cell and gene therapy company developing immuno-oncology solutions through use of oncolytic viruses and CAR T-cells – two immunotherapies with the promising ability of boosting a patient’s immune system to help it fight cancer. The company’s iTANK technology platform takes these therapies to a whole new level by enhancing a patient’s immune system even further, giving rise to a multifaceted attack on tumours, something the competition is struggling to provide. BioStock has now published a status report of the company that can be downloaded at biostock.se.
Read the Elicera Therapeutics status report at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/